


I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on June 25, 2008.

PATENT
Docket No.: 15270J-004766US
Client Ref. No.: 209-US-CIP8BC2C1

TOWNSEND and TOWNSEND and CREW LLP

By:



Rosemarie L. Celli, Reg. 42,397

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: 10/777,792

Filed: February 11, 2004

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Customer No.: 20350

Confirmation No.: 3041

Examiner: Daniel E. Kolker

Art Unit: 1649

REQUEST FOR CORRECTED
FILING RECEIPT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Issuance of a corrected filing receipt is respectfully requested. Attached hereto is a marked-up copy of the Official Filing Receipt mailed by the U.S. Patent and Trademark Office on June 3, 2008.

Applicant requests the filing receipt be corrected as follows:

Please correct the name of the Assignment For Published Patent Application; to delete "Neuralab Ltd" and replace it with "Elan Pharma International Limited, Athlone, IRELAND" (see attached Supplemental Application Data Sheet filed October 30, 2007 and Statement under 37 CFR 3.73(b) filed on October 30, 2007 and resubmitted June 25, 2008).


Please correct the Power of Attorney; to delete

"William Smith 30223
Jean Duvall 32731
Nina Ashton 37273
Joe Liebeschuetz 37505"

and replace with "The practitioners associated with Customer Number 20350"
(see attached Power of Attorney filed on October 30, 2007 and resubmitted June 25, 2008)

Applicant believes no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the previously noted deposit account

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
RLC/tat



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NUMBER | FILING or 371(c) DATE | GRP ART UNIT | FIL FEE RECD | ATTY. DOCKET NO | TOT CLAIMS | IND CLAIMS |
|-----------------------|--------------------------|-----------------|--------------|-----------------|------------|------------|
| 10/777,792 | 02/11/2004 | 1649 | 2126 | 15270J-004766US | 50 | 2 |

CONFIRMATION NO. 3041

CORRECTED FILING RECEIPT



0C000000030261859

20350

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

Date Mailed: 06/03/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Dale B. Schenk, Burlingame, CA;

Assignment For Published Patent Application

~~Neurelab Ltd~~ Elan Pharma International Limited, Athlone, IRELAND

Power of Attorney:

The patent practitioners associated with Customer Number 20350

~~William Smith - 30223~~~~Jean Duvall - 32731~~~~Nina Ashton - 37273~~~~Joe Liebeschuetz - 37505~~

Domestic Priority data as claimed by applicant

This application is a CON of 09/723,544 11/28/2000 ABN
which is a CON of 09/580,018 05/26/2000 PAT 6,761,888

Foreign Applications

If Required, Foreign Filing License Granted: 05/08/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
is **US 10/777,792**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

Prevention and treatment of amyloidogenic disease

Preliminary Class

424

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER**Title 35, United States Code, Section 184****Title 37, Code of Federal Regulations, 5.11 & 5.15****GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Application Data Sheet

Application Information

| | |
|---------------------------------|--|
| Application number:: | 10/777,792 |
| Filing Date:: | 2/11/04 |
| Application Type:: | Regular |
| Subject Matter:: | Utility |
| Sequence Submission:: | Yes |
| Number of copies of CDs:: | |
| Computer Readable Form (CRF)?:: | No |
| Title:: | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE |
| Attorney Docket Number:: | 15270J-004766US |
| Request for Early Publication:: | No |
| Request for Non-Publication:: | No |
| Total Drawing Sheets:: | 18 |
| Small Entity?:: | No |
| Petition included?:: | No <u>Yes</u> |
| Secrecy Order in Parent Appl.:: | No |

Applicant Information

| | |
|----------------------------------|---------------|
| Applicant Authority Type:: | Inventor |
| Primary Citizenship Country:: | US |
| Status:: | Full Capacity |
| Given Name:: | Dale |
| Middle Name:: | B. |
| Family Name:: | Schenk |
| Name Suffix:: | |
| City of Residence:: | Burlingame |
| State or Province of Residence:: | CA |
| Country of Residence:: | US |

Street of Mailing Address:: 1542 Los Altos Drive
City of Mailing Address:: Burlingame
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94010

Applicant Authority Type:: Inventor
Primary Citizenship Country:: France
Status:: Full Capacity
Given Name:: Frederique
Middle Name::
Family Name:: Bard
Name Suffix::
City of Residence:: Pacifica
State or Province of Residence:: CA
Country of Residence:: US
Street of Mailing Address:: 1111 Park Pacifica Avenue
City of Mailing Address:: Pacifica
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94044

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Theodore
Middle Name::
Family Name:: Yednock
Name Suffix::

City of Residence:: Forest Knolls
 State or Province of Residence:: CA
 Country of Residence:: US
 Street of Mailing Address:: 184 Arroyo Road
 City of Mailing Address:: Forest Knolls
 State or Province of mailing address:: CA
 Country of mailing address:: US
 Postal or Zip Code of mailing address:: 94933

Correspondence Information

Correspondence Customer Number:: 20350

Representative Information

Representative Customer Number:: 20350

Domestic Priority Information

| Application:: | Continuity Type:: | Parent Application:: | Parent Filing Date:: |
|------------------|------------------------------------|----------------------|----------------------|
| This Application | Continuation of | 09/723,544 | 11/28/00 |
| 09/723,544 | Continuation in part of | 09/580,018 | 05/26/00 |
| 09/580,018 | Continuation in part of | 09/322,289 | 05/28/99 |
| 09/322,289 | Continuation in part of | 09/201,430 | 11/30/98 |
| 09/201,430 | Application Claiming | 60/080,970 | 04/07/98 |
| | Benefit Under 35 | | |
| | U.S.C. Section 110(e) | | |

Assignee Information

Assignee Name:: ~~Neuralab Limited~~ Elan Pharma International Limited
 Street of mailing address:: ~~402 St. James Court~~ Monksland

City of mailing address:: FlattsAthlone
State or Province of mailing address:: SmithsCounty Westmeath
Country of mailing address:: BermudaIreland



PTO/SB/81 (01-08)

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

| | |
|------------------------|--|
| Application Number | 10/777,792 |
| Filing Date | February 11, 2004 |
| First Named Inventor | Schenk, Dale B. |
| Title | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE |
| Art Unit | 1649 |
| Examiner Name | Kimberly A. Ballard * |
| Attorney Docket Number | 15270J-004766US |

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

Practitioners associated with the Customer Number:

20350

OR

Practitioner(s) named below:

| Name | Registration Number |
|------|---------------------|
| | |
| | |
| | |
| | |

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number:

OR

The address associated with Customer Number:

OR

| | | | |
|----------------------------|-------|-----|-------|
| Firm or Individual Name | | | |
| Address | | | |
| City | State | Zip | |
| Country | | | |
| Telephone | | | Email |

I am the:
Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

| | | | |
|------------------|--|-----------|------------------|
| Signature |  | Date | OCTOBER 22, 2007 |
| Name | WILLIAM DANIEL | Telephone | 353-1-709 4000 |
| Firm and Company | ELAN PHARMA INTERNATIONAL LIMITED | | |

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of 1 form is submitted.

61184300 v1



STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Dale B. Schank et al.

Application No./Patent No.: 10/777,792

Filed/Issue Date: February 11, 2004

Entitled: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Elan Pharma International Limited, a corporation

(Name of Assignee)

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest; or
2. an assignee of less than the entire right, title and interest.
(The extent (by percentage) of its ownership interest is _____%)

in the patent application/patent identified above by virtue of either:

- A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a true copy of the original assignment is attached.

OR

- B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Schenk, Dale B.; Bard, Frederique; Yednock, Theodore To: Elan Pharmaceuticals, Inc.

The document was recorded in the United States Patent and Trademark Office at
Reel 011230, Frame 0598, or for which a copy thereof is attached.

2. From: Elan Pharmaceuticals, Inc. To: Neuralab Limited

The document was recorded in the United States Patent and Trademark Office at
Reel 011230, Frame 0585, or for which a copy thereof is attached.

3. From: Neuralab Limited To: Elan Pharma International Limited

The document was recorded in the United States Patent and Trademark Office at
Reel 017846, Frame 0480, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

[Signature]
Signature

October 22, 2007
Date

WILLIAM DANIEL
Printed or Typed Name

353 1 709 4000
Telephone Number

DIRECTOR
Title